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Abstract- Enfuvirtide is a first of its class as a fusion inhibitor 
drug which inhibits the fusion of HIV-1 virus with CD4+ cells on 
the target organism with a human therapeutic dose of 90mg/twice 
daily.  It  is  a  linear  36  amino  acid  peptide  with  the  empirical 
formula C204H30N51O64, and the molecular weight of 4.4Kd. The 
present  study  was  conducted  to  investigate  the  repeat  dose 
toxicity of recombinant Enfuvirtide, which was manufactured in-
house, when administered twice daily subcutaneously for twenty 
eight  consecutive  days  in  New  Zealand  white  rabbits  at  dose 
levels  of  4.2  mg/kg  bw  (Therapeutic  Dose),  10.5  mg/kg  bw 
(Average Dose) and 21.0 mg/kg bw (High Dose) in comparison 
with  synthetic  enfuvirtide.  The  animals  were  observed  during 
this period for mortality/morbidity, clinical signs, body weight, 
food consumption, hematology and clinical chemistry.  At the 
end of the experimental period all the animals were necropsied 
and vital organs were weighed and subjected to histopathological 
examination.  In  conclusion,  No  repeated  administration  of 
recombinant Enfuvirtide for a period of 28 days did not exert any 
toxic effects in rabbits at different dose levels. 
 
Index Terms- 28-Day Subchronic Oral Toxicity, Enfuvirtide, 
HIV-1Virus, NewZealand White Rabbits, OECD Guidelines Test 
No.407. 
 
I.  INTRODUCTION 
he use of synthetic peptides as HIV-1 inhibitors has been the 
object  of  research  over  recent  years.  A  large  number  of 
peptides that affect different stages of the HIV-1 life cycle have 
been  and  continue  to  be  studied  due  to  their  possible  clinical 
application  in  the  fight  against  HIV-1  infection.  The  main 
advantages of synthetic peptides as therapeutic agents are their 
low systemic toxicity, the fact that structural modifications can 
be made to them and their resulting capacity to mimic certain 
substrates  or  epitopes.  HIV-1-inhibiting  peptides  have  been 
identified and/or developed using different methods. 
      Although combination antiretroviral therapy has dramatically 
improved  the  lives  of  patients  with  human  immunodeficiency 
virus (HIV) infection, viral strains that are resistant to multiple 
medications are a serious problem. The durability of suppression 
of  human  immunodeficiency  virus  (HIV)  infection  with 
antiretroviral  therapy  is  often  limited,  for  reasons  that  include 
poor  penetration  into  protected  sites  containing  a  reservoir  of 
HIV [1], drug toxicity [2], alterations in the bioavailability and 
metabolism  of  antiretroviral  drugs  (e.g.,  interactions  between 
drugs) [3] and lack of adherence to complex treatment regimens 
[4].  These  factors  contribute  to  persistent  viral  replication  in 
patients receiving therapy, increasing the risk of viral resistance, 
which can limit future treatment options [5]. 
      Enfuvirtide (also known as T-20) is a novel, synthetic, 36-
amino-acid  peptide  that  binds  to  a  region  of  the  envelope 
glycoprotein 41 of HIV type 1 (HIV-1) that is involved in the 
fusion of the virus  with the  membrane of the  CD4+ host cell 
[6]. This agent exhibits potent and selective inhibition of HIV-1 
in vitro without cytotoxicity [7] and is the first inhibitor of HIV 
entry to show consistent potent activity in persons infected with 
HIV-1[8]. Enfuvirtide interferes with the entry of HIV-1 in to 
cells by inhibiting fusion of viral and cellular membranes. The 
HIV-1 viral envelope glycoprotein consists of two noncovalently 
associated  subunits,  a  surface  glycoprotein  (gp120)  and  a 
transmembrane  glycoprotein  (gp41)  [9].  Gp41  undergoes 
conformational rearrangements which accelerates the fusion of 
viral and cellular membranes that causes viral entry into the host 
and integrates into the host genome and finally express it. As a 
result  the  formation  of  six  helix  bundle,  viral  and  cellular 
membrane comes together and allowing them to fuse with each 
other. Recombinant Enfuvirtide, binds to the first heptad-repeat 
(HR1) in the gp41 subunit of the viral envelope glycoprotein and 
prevents the conformational changes required for the fusion of 
viral and cellular membranes [10]. 
      Enfuvirtide  originated  at Duke  University  and  the 
development  of  enfuvirtide  was  started  in  1996  and  initially 
designated as T-20. It was approved by the U.S. Food and Drug 
Administration (FDA) on March 13, 2003 as the first HIV fusion 
inhibitor,  a  new  class  of  antiretroviral  drugs.  Since  the 
production  of  T20  by  synthetic  methods  is  expensive  and 
cumbersome,  an  alternative  recombinant  approach  for  the 
production of the T20 peptide through a novel short fusion-tag 
expression  system  has  been  reported  [11].  Moreover,  the 
treatment with T20 involves high therapeutic doses. Production 
of  therapeutic  products  by  the  rDNA  technology  has  several 
advantages,  such  as  provision  of  drugs  that  could  not  be 
produced  by  conventional  methods,  manufacture  of  sufficient 
quantities of drugs at lower cost, lowers the manufacturing cost 
and steps involved in the production of the drug and provision 
for manufacturing safe drugs. 
      Although  several  articles  are  available  regarding  the 
pharmacological activity of the product, literature regarding the 
safety profile is scarce. Hence, the current study was carried out 
to  assess  the  repeat  dose  toxicity  effects  of  recombinant 
Enfuvirtide, when administered subcutaneously for a period of 
28 days to male and female New Zealand White Albino Rabbits 
at various dose levels as mentioned in the test system. Rabbits 
were selected as the testing species because one rodent and one 
non-rodent are mandatory as per the regulatory requirement. The 
dose  levels  were  calculated  based  on  the  body  surface  area 
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(BSA)  ratio  factor,
  and  the  route  of  administration  of  test 
compound  is  subcutaneous  which  was  similar  to  that  of 
innovator’s  synthetic  enfuvirtide  (Brand  name:  Fuzeon,  Roche 
Laboratories Inc.,). 
 
II.  MATERIALS AND METHODS 
      EthicalClearance - The study was carried out in compliance 
with the ‘Guidelines for Laboratory Animals Facility’ issued by 
the  Committee  for  the  Purpose  of  Control  and  Supervision  of 
Experiments  on  Animals  (CPCSEA),  India.  These  guidelines 
promote  the  humane  care  of  animals  used  in  research  by 
providing  specifications  that  will  enhance  animals’  well  being 
and  experimental  quality  for  the  advancement  of  biological 
knowledge that is relevant to humans and animals. 
      Institutional  Animal  Ethics  Committee  (IAEC)  had 
recommended and CPCSEA had approved the project proposal. 
 
Experimental Conditions 
      Animal  Husbandry  -  The  conduct  of  a  repeat  dose  oral 
toxicity  study  is  a  requirement  of  worldwide  drug  regulatory 
agencies [12-15] for intended use in humans. Rabbit is a standard 
non  rodent  species  used  in  toxicology  studies  based  upon  the 
substantial amount of published historical data on the suitability 
for such studies.  The number of animals used in this study is 
based upon worldwide regulatory guidelines [12-15]. 
      Animals  were  allowed  to  acclimatize  to  the  experimental 
conditions for a period of 7 days prior to treatment. During the 
acclimatization  period,  the  animals  were  observed  daily  for 
clinical  signs  of  any  existing  disease.  Prior  to  grouping,  a 
detailed  physical  examination  was  performed  on  all  the 
experimental  animals.  Animals  were  maintained  in  an 
environment-controlled room at a temperature of 20 ± 3 °C and 
relative  humidity  of  30  to  70  per  cent.    Rabbits  were  housed 
individually. The experimental animals were fed ad libitum with 
standard pellet feed and Lucerne grass. 
 
      Route  of  administration  -  Recombinant  Enfuvirtide  was 
administered subcutaneously as it is the recommended route of 
administration in humans. 
 
      Experimental procedure - Animals were randomized into 7 
groups and the test compound was administered to each group of 
3 males and 3 females twice daily, subcutaneously for a period of 
28 days. After 28 days of repeated administration, animals from 
group I (VC), II (TD), III (TD(I)), IV (AD) and V (HD) were 
sacrificed  and  tissues  and  blood  samples  were  collected  and 
stored  for  further  investigations.  The  two  additional  satellite 
groups i.e. Group VI and Group VII (Satellite VC and HD) were 
observed for reversibility, persistence, or delayed occurrence of 
toxic effects for a post treatment of 14 days. The recovery group 
animals  were  sacrificed  on  day  43  and  various  investigations 
were conducted as per the schedule. 
      Dosing - Formulated recombinant Enfuvirtide in dose levels 
of 4.2 mg/kg bw (Therapeutic Dose), 10.5 mg/kg bw (Average 
Dose) and 21.0 mg/kg bw (High Dose and Satellite High Dose) 
twice  daily  for  a  period  of  28  days.  Vehicle  Control  groups 
(Vehicle  Control  and  Satellite  Vehicle  Control)  were 
administered with formulation buffer. Animals were observed for 
a  period  of  28  days  till  the  last  administration  of  the  test 
compound. 
      Observations  -  Mortality  rate,  In-life  and  cage  side 
examinations  were  done  regularly,  hematology,  clinical 
chemistry was carried on day 0 and day 29 for main groups and 
on  day  0  and  43  for  recovery  groups.  Gross  necropsy  was 
performed  on  both  main  group  and  recovery  group  animals. 
Brain,  thymus, spleen, bone marrow, kidney, wound site/ site of 
application, heart, lung, trachea, thyroid, sternum, liver, gastro 
intestinal  tract,  testes  and  ovaries  were  collected  from  all  the 
animals  and  preserved  in  10%  buffered  neutral  formalin  for 
histopathological analysis  
      Statistical Analysis - Treatment groups were compared with 
vehicle  control  by  Fisher's  exact  or  Chi-square  test.  Between 
group  comparisons  by  means  of  Kruskal-Wallis  one-way 
ANOVA and individual group comparisons by Mann-Whitney U 
test (treatment groups with vehicle control) were the method of 
analysis. Two-tailed probability level of 0.05  was  set in  these 
experiments for rejecting the null hypothesis. 
 
III.  RESULTS AND DISCUSSION 
      Recombinant  Enfuvirtide  was  administered  twice  a  day 
subcutaneously to Newzealand white rabbits for a period of 28 
days  at  different  dose  levels.  In  comparison  with  the  vehicle 
control and Innovator therapeutic group Enfuvirtide did not show 
any  significant  changes  in  the  in  physical  and  physiological 
parameters  which  were  assessed  throughout  the  experimental 
period.  
      All  the  male  and  female  animals  from  control  and  all  the 
treated dose groups survived throughout the dosing period of 28 
days and the recovery period of 14 days. No signs of intoxication 
were observed in male and female rabbits of main and recovery 
groups during the 28 days dosing period and 14 day recovery 
period.  Local  tolerance  of  recombinant  Enfurvirtide  was 
evaluated as a clinical observation and morphologic pathology of 
injection site. No adverse effects such as irritation, inflammation 
and edema  were noticed at the site of injection. No treatment 
related weight loss was observed in all the animals.  
      Male and female animals from all the treated dose groups 
exhibited  comparable  body  weight  gain  with  that  of  controls 
throughout the study period. Food consumption of control and 
treated  animals  was  found  to  be  comparable  throughout  the 
dosing period of 28 days and the recovery period of 14 days. In-
life phase and cage side observations, conducted throughout the 
study period on control and the treated group animals did not 
reveal any abnormality. Hematological analysis conducted at the 
end of the dosing period on day 29 and at the end of recovery 
period on day 43, revealed no abnormalities attributable to the 
treatment.  
      Clinical chemistry profile of main group and recovery group 
animals did not reveal any significant results attributable to the 
treatment. Organ weight data of male and female sacrificed at the 
end of the dosing period and at the end of the recovery period 
was  found  to  be  comparable  with  that  of  respective  controls.  
Gross pathological examination did not reveal any abnormality. 
Histopathological  examination  did  not  reveal  any  treatment 
related abnormalities 
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TABLE –I(a) 
SUB-CHRONIC STUDY –RABBIT MALE & FEMALE 




Days  of 
observation 
VC         TD       TD(I)  AD  HD 
M  F  M  F  M  F  M  F  M  F 
1  Base line  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3 
2  1  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3 
3  2  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3 
4  3  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3 
5  4  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3 
4  5  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3 
7  6  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3 
8  7  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3 
9  8  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3 
10  9  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3 
11  10  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3 
12  11  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3 
13  12  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3 
14  13  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3 
15  14  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3 
16  15  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3 
17  16  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3 
18  17  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3 
19  18  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3 
20  19  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3 
21  20  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3 
22  21  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3 
23  22  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3 
24  23  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3 
25  24  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3 
26  25  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3 
27  26  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3 
28  27  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3 
29  28  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3  0/3 
 
TABLE –I(b) 
SUB-CHRONIC STUDY –RABBIT MALE & FEMALE 
MORTALITY OF RABBIT EXPOSED TO TEST COMPOUND 
 
S.No  Days  of 
observation 
     SVC         SHD 
M  F  M  F 
1  Baseline  0/3  0/3  0/3  0/3 
2  2  0/3  0/3  0/3  0/3 
3  4  0/3  0/3  0/3  0/3 
4  6  0/3  0/3  0/3  0/3 
5  8  0/3  0/3  0/3  0/3 
4  10  0/3  0/3  0/3  0/3 
7  12  0/3  0/3  0/3  0/3 
8  14  0/3  0/3  0/3  0/3 
9  16  0/3  0/3  0/3  0/3 
10  18  0/3  0/3  0/3  0/3 
11  20  0/3  0/3  0/3  0/3 
12  22  0/3  0/3  0/3  0/3 
13  24  0/3  0/3  0/3  0/3 
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15  28  0/3  0/3  0/3  0/3 
16  30  0/3  0/3  0/3  0/3 
17  31  0/3  0/3  0/3  0/3 
18  32  0/3  0/3  0/3  0/3 
19  33  0/3  0/3  0/3  0/3 
20  34  0/3  0/3  0/3  0/3 
21  35  0/3  0/3  0/3  0/3 
22  36  0/3  0/3  0/3  0/3 
23  37  0/3  0/3  0/3  0/3 
24  38  0/3  0/3  0/3  0/3 
25  39  0/3  0/3  0/3  0/3 
26  40  0/3  0/3  0/3  0/3 
27  41  0/3  0/3  0/3  0/3 
28  42  0/3  0/3  0/3  0/3 
29  43  0/3  0/3  0/3  0/3 
                                     
 
TABLE – II(a) 
BODY WEIGHT - (kg) MALE 
 
Groups  Base line  3
st  day  7
rd  day  11
th  day  14



























































































































TABLE II (b) 
BODY WEIGHT - (kg)  FEMALE 
 
Groups  Base line  3
st  day  7
rd  day  11
th  day  14
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Values are expressed as Mean ± SD    
 
TABLE – III (a) 
FOOD INTAKE (gm) MALE 
 
Groups  Base line  3
st  day  7
rd  day  11
th  day  14

























































































































TABLE – III (b) 
FOOD INTAKE (gm) FEMALE 
 
Groups  Base line  3
st  day  7
rd  day  11
th  day  14
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TABLE-IV (a) 
HEMATOLOGY PARAMETERS - MALE 
 
Groups  VC  TD 
TD(I) 
AD  HD 
Days  (Post 
exposure)  0  28  0  28  0  28  0  28  0  28 
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TABLE-IV (a) continued ……. 
 
 
Groups  SVC  SHD 
Days (Post exposure)  0  28  0  28 
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TABLE - IV (b) 
HEMATOLOGY PARAMETERS – FEMALE 
 
Groups  VC  TD 
TD(I) 
AD  HD 
Days  (Post 
exposure)  0  28  0  28  0  28  0  28  0  28 
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TABLE –V (a) 
BIOCHEMICAL PARAMETERS – MALE 
 
Groups  VC  TD  TD(I)  AD  HD 
Days  (Post 
exposure)  0  28  0  28  0  28  0  28  0  28 
Parameters                     

































































Groups   SVC   SHD 
Days (Post exposure)  0  28  0  28 
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Groups  SVC  SHD 
Days (Post exposure)  0  28  0  28 
Parameters         
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TABLE- V (b) 
BIOCHEMICAL   PARAMETERS – FEMALE 
 
Groups  VC  TD  TD(I)  AD  HD 
Days (Post exposure)  0  28  0  28  0  28  0  28  0  28 
Parameters                     
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TABLE V(b) continued …….. 
 
 
























































Groups  SVC  SHD 
Days (Post exposure)  0  28  0  28 
Parameters         
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TABLE – VI(a) 
URINE EXAMINATION - MALE 
 
S. No  Parameters  DAY   
VC  TD  TD(I)  AD  HD  SVC  SHD 


























































































































































































































































































































6  pH  0
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TABLE- VI (b) 
URINE EXAMINATION – FEMALE 
 
S. No  Parameters  DAY   
VC  TD  TD(I)  AD  HD  SVC  SHD 
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3  28
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Values are in percentage                                                            
 
 
TABLE  - VII(a) 
ORGAN WEIGHTS (gm) - MALE 
 












                   




TD(I)  AD 
 
HD  SVC 
 
SHD 
Days  (Post 
exposure)  28  28  28  28 
 
28  28 
 
28 
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TABLE  - VII(b) 
ORGAN WEIGHTS (gm) - FEMALE 
 
Values are expressed as Mean  ± SD                                                       
 
IV.  CONCLUSION 
       In  conclusion,  no  specific  outcome  of  toxicological 
significance  was  noted  with  the  repeated  administration  of 
recombinant Enfuvirtide as compared to the Vehicle control and 
Innovator’s synthetic enfuvirtide. 
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